COAG (Hemab Therapeutics Holdings) Beginning Cash Position: $74.41 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $44.73
! 1 Warning Sign
View Full Analysis

What is Hemab Therapeutics Holdings Beginning Cash Position?

Hemab Therapeutics Holdings COAG +1.54% 11 Beginning Cash Position is $74.41 Mil as of Dec. 2025. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Hemab Therapeutics Holdings's Beginning Cash Position for the quarter that ended in Dec. 2025 was $74.41 Mil.

Hemab Therapeutics Holdings's quarterly Beginning Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($58.20 Mil) and increased from Dec. 2024 ($58.20 Mil) to Dec. 2025 ($74.41 Mil).

Hemab Therapeutics Holdings's annual Beginning Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($58.20 Mil) and increased from Dec. 2024 ($58.20 Mil) to Dec. 2025 ($74.41 Mil).

Hemab Therapeutics Holdings Beginning Cash Position Related Terms

Hemab Therapeutics Holdings Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings Beginning Cash Position Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
Beginning Cash Position
58.20 74.41

Hemab Therapeutics Holdings Semi-Annual Data
Dec24 Dec25
Beginning Cash Position 58.20 74.41
COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $74.41 Mil mean?
Hemab Therapeutics Holdings (COAG) has a Beginning Cash Position of $74.41 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Hemab Therapeutics Holdings and its competitors.
Is Hemab Therapeutics Holdings' Beginning Cash Position too high?
Hemab Therapeutics Holdings' current Beginning Cash Position is $74.41 Mil. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Beginning Cash Position compare to ADMA and VCEL?
Hemab Therapeutics Holdings' Beginning Cash Position of $74.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Hemab Therapeutics Holdings and its competitors. Hemab Therapeutics Holdings's current Beginning Cash Position is $74.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Beginning Cash Position of $74.41 Mil. The current Beginning Cash Position is $74.41 Mil. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Beginning Cash Position is $74.41 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.73
Price